Mydecine Innovations Group
Biotechnology
Denver, CO 2,661 followers
Reimagining Safer and More Effective Treatments for Mental Health and Addiction
About us
Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. The company's world-renowned medical and scientific advisory board is progressing a robust research and development (R&D) pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems.
- Website
-
https://www.mydecine.com/
External link for Mydecine Innovations Group
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Denver, CO
- Type
- Public Company
- Founded
- 2020
- Specialties
- mycology, fungi, psychedelics, genetics, therapy, telehealth, clinical trials, drug development, Intelectual property, mental health, and addiction
Locations
-
Primary
Get directions
Denver, CO 80211, US
Employees at Mydecine Innovations Group
-
Robert Roscow
CEO Roscow Biofuels - CSO Mydecine - Mydecine Board Director - Director of Genetics Victory Hemp Foods - Inventor and Biologist
-
Gary H. Wynn, MD, DFAPA
Consultant Psychiatrist & Professor of Psychiatry and Neuroscience
-
Rakesh Jetly
Chief Medical Officer at Mydecine Innovations Group